Jump to content

Zytiga (abiraterone) before chemo to be considered for PBS in July


Recommended Posts

Zytiga (abiraterone) is already in the Pharmaceutical Benefits Scheme (PBS) for men who have failed chemotherapy.


At their July meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) will decide whether it should recommend to the government that Zytiga should be listed on the PBS for men who have failed androgen deprivation therapy (ADT or hormone therapy), but who have not yet had chemotherapy.


Submissions can be sent by anyone with an interest, including patients and the people who care for them.


Submissions must be received by the committee by Wednesday 11 June 2014.


As with the earlier Zytiga decision submissions, we hope to have more information posted in the next few days to assist those wishing to make a submission.


But if you're happy with the online process and know what you wish to say, you can make your own submission here:






Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...